BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28

• 

  Policy

  How COVID-19 Has Permanently Changed The World of Medical Research

  A spirit of urgency and collaboration broke down traditional informational barriers as industry and academia organized like never before in modern history to develop a vaccine in just nine months.

  February 1, 2021

   · 

  5 min read

   · 

  Heather McKenzie
• 

  Drug Development

  Merck’s Keytruda Proves Better Alone in Combination Trial With BMS’ Yervoy

  Adding Yervoy to the therapy did not improve overall survival (OS) or progression-free survival (PFS) but did add toxicity to Keytruda monotherapy.

  February 1, 2021

   · 

  3 min read

   · 

  Mark Terry
• 

  Business

  Biosimilars Company Switches Gears to Immuno-Oncology with $150 Million Deal

  Junshi receives upfront payment of $50 million for U.S. and Canadian rights to its immuno-oncology drug.

  February 1, 2021

   · 

  2 min read

   · 

  Kate Goodwin
• 

  Business

  Clover Bio Dumps GSK Adjuvant Technology, Will Take Dynavax to Vaccine Dance

  China’s Clover Biopharmaceuticals is spurning GlaxoSmithKline’s adjuvant vaccine technology in favor of one created by California-based Dynavax Technologies.

  February 1, 2021

   · 

  2 min read

   · 

  Alex Keown
• 

  Business

  Gilead and Gritstone Ink $785 Million+ Deal to Develop HIV Cure

  Gilead Sciences has inked a collaboration, option and license deal with Gritstone Oncology to create a vaccine-based immunotherapy as a cure for HIV.

  February 1, 2021

   · 

  3 min read

   · 

  Mark Terry
• 

  Genetown

  Cellino Raises $16 Million Seed Round for AI-Guided Cell Therapies

  The round was led by The Engine, a venture capital firm born at Massachusetts Institute of Technology, and Khosla Ventures and joined by Humboldt Fund and 8VC.

  February 1, 2021

   · 

  2 min read

   · 

  Mark Zipkin
• 

  Deals

  Horizon Therapeutics Augments Rare Disease Portfolio with Viela Bio Buy

  Shares of Viela Bio skyrocketed more than 52% in premarket trading after Ireland’s Horizon Therapeutics announced it was acquiring the company in a $3.05 billion deal.

  February 1, 2021

   · 

  3 min read

   · 

  Alex Keown
• 

  Drug Development

  Concert Pharmaceuticals Switches Focus After Schizophrenia Drug Falls Flat

  Concert Pharmaceuticals said its Phase II clinical trial for its adjunctive schizophrenia treatment, CTP-692, did not meet the primary endpoint or other secondary endpoints, causing the company to halt development of the drug.

  February 1, 2021

   · 

  3 min read

   · 

  Brandon May
• Artificial Eyes Demand Driven by Growing Prevalence of Ophthalmic Diseases, Says Fact.MR

  Fact.MR, a global research and consulting firm, in the updated edition of the report, opines artificial eyes market to expand at a robust rate in 2021 & beyond.

  February 1, 2021

   · 

  4 min read
• Image-Based Cytometer Market: Growth Dynamics & Competitive Analysis

  Image-based cytometry can be defined as a technology that offers a combination of imaging analysis and microfluidics.

  February 1, 2021

   · 

  4 min read